参脉注射液在支气管哮喘的临床应用

Clinical observation on treating bronchus asthma with Shenmai injection

目的:为了探讨临床有效治疗支气管哮喘的方法,从而为支气管哮喘的临床治疗的相关研究提供可靠依据。方法:本次研究所选取的研究对象,均为2012年5月-2014年4月期间我院收治的支气管哮喘患者,全部患者共计128例。随机对患者进行分组,分成对照组(常规西医治疗)和观察组(常规西医治疗的基础上加用参脉注射液),每组64例研究对象。观察比较两组研究对象实施不同临床治疗方法后的治疗效果以及CD_4^+(%)、CD_8^+(%)、CD_4^+/CD_8^+比值等细胞免疫功能指标。结果:①临床总有效率组间比较,观察组患者的总有效率水平显著的高于对照患者,且组间数据比较差异具有显著的统计学意义(x^2=10.7581,P=0.0010);②在CD_4^+、CD_8^+和CD_4^+/CD_8^+比值等三项指标上,组问比较,观察组患者三项指标水平均显著的优于对照组患者,且组间数据比较差异具有显著的统计学意义(P<0.05)。结论:在临床治疗支气管哮喘的实践过程中,采用参脉注射液实施治疗的临床效果显著,是临床治疗支气管哮喘的可靠选择。

Objective： To discuss effective methods on treating bronchus asthma, and provide reliable reference for treatment. Methods： 128 patients were randomly divided into two groups, 64 cases for each, the control was given the routine western medicine, while the observation was given the Shenmai injection more. Clinical effects and index of CD4^＋（%）, CD8^＋（%）, CD4^＋/CD8^＋, were observed. Results： Ⅰ. The total efficacy in the observation was obviously higher than the control, the difference was statistically significant （χ^2=10.7581, P=0.0010）; Ⅱ. index level of CD4^＋, CD8^＋, CD4^＋/CD8^＋ in the observation was higher, the difference was statistically significant （P〈0.05）. Conclusion： Shenmai injection shows great effects in clinic, was available in treating bronchus asthma.